MoonLake Immunotherapeutics（MLTX）今日盘前股价暴跌86.24%，引起市场广泛关注。这一大幅下跌主要源于两个因素：公司最新临床试验结果的发布以及分析师的评级下调。
首先，MoonLake Immunotherapeutics公布了其Vela三期化脓性汗腺炎临床项目的第16周试验结果。该项目正在评估纳米抗体®Sonelokimab的疗效。虽然具体结果尚未详细披露，但市场对此反应强烈，暗示结果可能不及预期。
其次，加拿大皇家银行（RBC）大幅调整了对MoonLake Immunotherapeutics的评级。RBC将公司的投资评级从"跑赢大盘"下调至"板块表现"，同时大幅下调目标价，从此前的67美元降至10美元。这一调整反映了分析师对公司未来发展前景的担忧，进一步加剧了投资者的抛售情绪。这两个因素叠加，导致MLTX股价在盘前交易中出现如此剧烈的下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.